Page 1

Attovia Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO - 1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high - itch atopic dermatitis ( AD ) ; complete Phase 1b data expected in Q4 2026 Phase 2 studies of ATTO - 1310 in chronic pruritus of unknown origin and high - itch AD planned for 1H 2027 Phase 1 initiation for ATTO - 2306 and ATTO - 1091 planned in 1H 2027 Upsized Initial Public Offering ( IPO ) gross proceeds of $ 332.4 million helps extend cash runway into 2030 - SAN CARLOS , Calif . , September 2 , 2026 – Attovia Therapeutics , Inc. ( “ Attovia ” or the “ Company ” ) ( Nasdaq : ATTO ) , a clinical - stage biopharmaceutical company developing next - generation biotherapeutics for immune - mediated diseases with high unmet need , today reported financial results for the second quarter ended June 30 , 2026 and provided a corporate update . " Following the successful completion of our upsized IPO , Attovia enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near - term value - creating milestones , ” said Tao Fu , Founder and Chief Executive Officer of Attovia . “ The preliminary clinical proof of concept for ATTO - 1310 in chronic pruritus and high - itch AD provides important validation of both the program and our ATTOBODY platform . We are advancing ATTO - 1310 toward two large Phase 2 studies while progressing ATTO - 2306 and ATTO - 1091 toward the clinic in the first half of 2027. With multiple internally discovered programs moving through development , we remain focused on disciplined execution and building Attovia into a sustainable , multi - product biotechnology company with the goal of shaping the future of immune - mediated diseases . " Recent Pipeline Highlights and Upcoming Milestones ATTO - 1310 for pruritic diseases : a novel , highly potent , half - life extended ATTOBODY - based Fc - fusion protein targeting the itch cytokine IL - 31 . • Completed the Phase la study in healthy volunteers in which ATTO - 1310 demonstrated favorable tolerability , rapid and sustained suppression of IL - 31 , and low immunogenicity . Completed enrollment and dosing in the double - blind , placebo - controlled Phase 1b study in patients with chronic pruritus and high - itch AD . Preliminary results showed that a single dose of ATTO - 1310 was followed by rapid , deep itch relief in both patient populations , and consistent lesion control was demonstrated in patients with high - itch AD , providing clinical proof of concept for ATTO - 1310 and the ATTOBODY platform . Complete Phase 1b data are expected in the fourth quarter of 2026 . Submitted the protocol for the global Phase 2 study in patients with chronic pruritus of unknown origin ( CPUO ) to the U.S. Food and Drug Administration ( FDA ) after incorporating the agency's feedback on key design elements and endpoints . Study initiation is planned for the first half of 2027 . Global Phase 2 study in patients with high - itch AD is planned to initiate in the first half of 2027 .